Ventricular Septal Defect (VSD) is one of the most frequently diagnosed congenital cardiac anomalies, traditionally treated via open-heart surgery. With advancements in structural heart interventions, percutaneous device closure has emerged as a minimally invasive alternative, particularly in muscular and perimembranous VSDs. This study evaluates the clinical efficacy, procedural success, complication rates, hemodynamic outcomes, and long-term prognosis of patients undergoing percutaneous VSD closure. A total of 264 patients aged 3 months to 52 years underwent device closure using Amplatzer™, Lifetech Cera™, and Occlutech™ devices across three cardiac centers over five years. Procedural success was 95.8%, with major complications observed in 3.4% of patients. Hemolysis occurred in 1.9%, arrhythmias in 4.5%, and residual shunts in 6.2%. No device embolization occurred. The study concludes that percutaneous VSD closure is a safe and effective alternative to surgery in selected patients, offering reduced hospital stay, fewer complications, and faster rehabilitation.